Jangsik Shin

Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet · 2018 · 142 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +16

Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial

Issaka Sagara, Abdoul Habib Béavogui, Issaka Zongo et al. · The Lancet Infectious Diseases · 2015 · 87 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study

Gaston Tona Lutete, Ghyslain Mombo‐Ngoma, Serge-Brice Assi et al. · PLoS Medicine · 2021 · 49 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +14

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients

Amal Ayyoub, Janthima Methaneethorn, Michael Ramharter et al. · Antimicrobial Agents and Chemotherapy · 2015 · 36 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers

Carrie A. Morris, Stephen R. Dueker, Peter N. Lohstroh et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2014 · 18 citations

Medicine, Pharmacokinetics, Pharmacology +11